Online citations, reference lists, and bibliographies.

Tryptamine And Dimethyltryptamine Inhibit Indoleamine 2,3 Dioxygenase And Increase The Tumor-reactive Effect Of Peripheral Blood Mononuclear Cells.

Melissa Cavalheiro Tourino, Edson Mendes de Oliveira, Luziane Potrich Bellé, Franciele Hinterholz Knebel, Renata Chaves Albuquerque, Felipe Augusto Dörr, Sabrina Sayori Okada, Silene Migliorini, Irene S Soares, Ana Campa
Published 2013 · Biology, Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Indoleamine 2,3-dioxygenase (IDO) is an interferon-γ (IFN-γ)-induced tryptophan-degrading enzyme, producing kynurenine (KYN) that participates in the mechanism of tumor immune tolerance. Thus, IDO inhibition has been considered a strategy for anticancer therapy. The aim of this study was to identify whether the metabolites originated from the competitive routes of tryptophan metabolism, such as the serotonergic or N, N-dimethyltryptamine (DMT) pathways, have inhibitory effects on recombinant human IDO (rhIDO) activity. Serotonin and melatonin had no effect; on the other hand, tryptamine (TRY) and DMT modulated the activity of rhIDO as classical non-competitive inhibitors, with Ki values of 156 and 506 μM, respectively. This inhibitory effect was also observed on constitutively expressed or IFN-γ-induced IDO in the A172 human glioma cell line. TRY and DMT increased the cytotoxic activity of peripheral blood mononuclear cells (PBMCs) in co-culture assays. We conclude that the IDO inhibition by TRY and DMT contributed to a more effective tumor-reactive response by the PBMCs.
This paper references
10.1016/S0040-4020(00)01091-7
Synthesis of 5-(sulfamoylmethyl)indoles
Joan Bosch (2001)
10.1111/j.1600-065X.2008.00610.x
Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.
Jessica B. Katz (2008)
10.1007/s00702-009-0308-8
Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter
Nicholas V. Cozzi (2009)
10.2967/jnumed.110.083246
In Vivo Long-Term Kinetics of Radiolabeled N,N-Dimethyltryptamine and Tryptamine
Arturo Alberto Vitale (2011)
10.1006/meth.2001.1262
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
Kenneth J Livak (2001)
10.1158/0008-5472.CAN-06-2925
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.
De-Yan Hou (2007)
Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.
A Böyum (1968)
10.1016/j.semcancer.2005.07.008
Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention.
T. Whiteside (2006)
10.1097/01.cji.0000199193.29048.56
Immune suppression in the tumor microenvironment.
T. Gajewski (2006)
10.1126/science.1166127
The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator
D. Fontanilla (2009)
10.1006/geno.1999.5960
Human indolethylamine N-methyltransferase: cDNA cloning and expression, gene cloning, and chromosomal localization.
Mark A. Thompson (1999)
10.1038/478192a
Cancer: Why tumours eat tryptophan
George C Prendergast (2011)
10.1038/nature08506
Predicting new molecular targets for known drugs
Michael J. Keiser (2009)
10.1016/j.immuni.2005.03.013
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.
David H. Munn (2005)
10.1006/prep.2000.1214
Expression and purification of recombinant human indoleamine 2, 3-dioxygenase.
Tamantha K. Littlejohn (2000)
10.1002/ijc.10645
Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection.
Maria Friberg (2002)
10.1038/nrc1929
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Alexander J Muller (2006)
10.1146/annurev-immunol-031210-101324
Natural innate and adaptive immunity to cancer.
M. D. Vesely (2011)
10.1097/01.cmr.0000205016.31235.a9
Anti-tumoural activity of peripheral blood mononuclear cells against melanoma cells: discrepant in-vitro and in-vivo effects
Débora Joseph-Pietras (2006)
10.1126/scisignal.261pe12
When the Endogenous Hallucinogenic Trace Amine N,N-Dimethyltryptamine Meets the Sigma-1 Receptor
T P Su (2009)
10.1021/jm9014718
Rational design of indoleamine 2,3-dioxygenase inhibitors.
U. Röhrig (2010)



This paper is referenced by
10.1080/02791072.2014.960113
Immunological Effects of Ayahuasca in Humans
Rafael Guimarães Dos Santos (2014)
10.3389/fnins.2018.00536
N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function
Steven A. Barker (2018)
10.1186/s40168-019-0704-8
Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health
Kaitlyn Oliphant (2019)
10.1016/j.cellimm.2015.11.003
Myeloperoxidase in human peripheral blood lymphocytes: Production and subcellular localization.
Sabrina Sayori Okada (2016)
10.1039/c7md00109f
Advances in indoleamine 2,3-dioxygenase 1 medicinal chemistry
A. Coletti (2017)
10.1039/C9MD00208A
Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Xiu-xiu Wang (2019)
10.2210/PDB5WHR/PDB
Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate
Stefano Crosignani (2017)
10.3389/fcimb.2018.00013
Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism
Jing Gao (2018)
10.11606/T.9.2015.tde-26102015-093528
Ação de metabólitos da via das triptaminas em linhagens de melanomas
Janine Baptista Coimbra (2015)
10.1016/j.bcp.2014.01.035
Biosynthesis of N,N-dimethyltryptamine (DMT) in a melanoma cell line and its metabolization by peroxidases.
Melissa Medrano Gomes (2014)
10.3389/fimmu.2015.00358
Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities
Attila Szabó (2015)
10.1177/2050312113508389
Ayahuasca and cancer treatment
Eduardo E Schenberg (2013)
10.1016/j.brainresbull.2016.04.016
Neuropharmacology of N,N-dimethyltryptamine
Theresa M. Carbonaro (2016)
eview europharmacology of N , N-dimethyltryptamine heresa
M. Carbonaroa (2016)
10.1021/acs.jmedchem.5b00326
Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Ute F. Röhrig (2015)
10.1080/02791072.2014.960113
Immunological Effects of Ayahuasca in Humans
Rafael G. dos Santos (2014)
10.3389/fimmu.2018.01363
An Expanded Neuroimmunomodulation Axis: sCD83-Indoleamine 2,3-Dioxygenase—Kynurenine Pathway and Updates of Kynurenine Pathway in Neurologic Diseases
Li Bo (2018)
10.1007/s12035-016-0004-2
The Role of the Microbial Metabolites Including Tryptophan Catabolites and Short Chain Fatty Acids in the Pathophysiology of Immune-Inflammatory and Neuroimmune Disease
Gerwyn Morris (2016)
Structure guided discovery of inhibitors of indoleamine 2,3-dioxygenase (IDO1)
Sai Fung (2015)
10.2147/OTT.S119362
Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors
Bilal Zulfiqar (2017)
10.1016/j.phytochem.2018.07.003
Isolation, spectral characterization, molecular docking, and cytotoxic activity of alkaloids from Erythroxylum pungens O. E. Shulz.
Gabrielle Macedo Pereira (2018)
Semantic Scholar Logo Some data provided by SemanticScholar